Published in Cancer Weekly, November 27th, 2001
"Standard conditioning for allogeneic bone marrow transplantation induces high transplant-related mortality (TRM) in patients with a poor performance status," explained E.P. Alessandrino and colleagues at Policlinico San Matteo in Pavia.
A reduced-intensity thiotepa- and fludarabine-based regimen (TT-FLUDA) reduced the risk of fatal complications without compromising treatment efficacy, Alessandrino and coauthors reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.